Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
Clin. transl. oncol. (Print) ; 13(3): 148-155, mar. 2011. ilus, tab
Article in English | IBECS | ID: ibc-124630

ABSTRACT

Bisphosphonates (BPs) are widely used in the management of metastatic bone disease to reduce skeletal morbidity. Zoledronic acid (ZA), the most potent BP in clinical use, has demonstrated clinical utility in multiple tumour types. Preclinical data indicate that ZA may have direct antitumour activity, as has been demonstrated preclinically in both in vitro and in vivo experiments. The majority of preclinical studies showing antitumour effects have used high doses of ZA, making it difficult to translate these data to the clinical setting. This review summarises the published data on antitumour effects of ZA in tumour cell lines, mice experiments, and human clinical trials. Translational questions regarding drug dose, dose interval, and sequence with chemotherapy treatment are also addressed (AU)


Subject(s)
Humans , Animals , Male , Female , Antineoplastic Agents/pharmacology , Clinical Trials as Topic/methods , Imidazoles/pharmacology , Neoplasms/drug therapy , Imidazoles/therapeutic use , Bone Density Conservation Agents/pharmacology , Bone Density Conservation Agents/therapeutic use
2.
Ann Oncol ; 22(3): 515-523, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20603440

ABSTRACT

BACKGROUND: Inflammatory breast cancer (IBC) represents the most aggressive presentation of breast cancer. Women diagnosed with IBC typically have a poorer prognosis compared with those diagnosed with non-IBC tumors. Recommendations and guidelines published to date on the diagnosis, management, and follow-up of women with breast cancer have focused primarily on non-IBC tumors. Establishing a minimum standard for clinical diagnosis and treatment of IBC is needed. METHODS: Recognizing IBC to be a distinct entity, a group of international experts met in December 2008 at the First International Conference on Inflammatory Breast Cancer to develop guidelines for the management of IBC. RESULTS: The panel of leading IBC experts formed a consensus on the minimum requirements to accurately diagnose IBC, supported by pathological confirmation. In addition, the panel emphasized a multimodality approach of systemic chemotherapy, surgery, and radiation therapy. CONCLUSIONS: The goal of these guidelines, based on an expert consensus after careful review of published data, is to help the clinical diagnosis of this rare disease and to standardize management of IBC among treating physicians in both the academic and community settings.


Subject(s)
Biomarkers, Tumor/metabolism , Inflammatory Breast Neoplasms/diagnosis , Inflammatory Breast Neoplasms/therapy , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antineoplastic Agents/therapeutic use , Aromatase Inhibitors/therapeutic use , Diagnostic Techniques and Procedures , Female , Humans , Neoadjuvant Therapy , Neoplasm Invasiveness , Neoplasm Metastasis , Neoplasm Staging , Radiotherapy, Adjuvant , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Tamoxifen/therapeutic use , Trastuzumab
3.
BJOG ; 117(3): 348-55, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20015310

ABSTRACT

OBJECTIVE: In previous studies, we have shown a three to four times higher urban incidence of breast cancer and estrogen receptor-positive breast cancers in the Gharbiah Province of Egypt. We investigated the urban-rural incidence differences of gynaecologic malignancies (uterine, ovarian and cervical cancers) to explore if they show the same trend that we found for breast cancer. DESIGN: Cancer registry-based incidence comparison. SETTING: Gharbiah population-based cancer registry (GPCR), Tanta, Egypt. SAMPLE: All patients with uterine, ovarian and cervical cancer in GPCR from 1999 to 2002. METHODS: We calculated uterine, ovarian and cervical cancer incidence from 1999 to 2002. For each of the three cancers, we calculated the overall and age-specific rates for the province as a whole, and by urban-rural status, as well as for the eight districts of the province. RESULTS: Incidence of all three cancer sites was higher in urban than in rural areas. Uterine cancer showed the highest urban-rural incidence rate ratio (IRR = 6.07, 95% CI = 4.17, 8.85). Uterine cancer also showed the highest urban incidence in the oldest age group (70+ age category, IRR = 14.39, 95% CI = 4.24, 48.87) and in developed districts (Tanta, IRR = 4.14, 95% CI = 0.41, 42.04). Incidence rates by groups of cancer sites showed an increasing gradient of urban incidence for cancers related to hormonal aetiology, mainly of the breast and uterus (IRR = 4.96, 95% CI = 2.86, 8.61). CONCLUSIONS: The higher urban incidence of uterine cancer, coupled with our previous findings of higher incidence of breast cancer and estrogen receptor positive breast cancer in urban areas in this region, may be suggestive of possible higher exposure to environmental estrogenic compounds, such as xenoestrogens, in urban areas.


Subject(s)
Genital Neoplasms, Female/epidemiology , Rural Health/statistics & numerical data , Urban Health/statistics & numerical data , Adolescent , Adult , Age Distribution , Aged , Child , Child, Preschool , Egypt/epidemiology , Female , Humans , Incidence , Infant , Infant, Newborn , Middle Aged , Ovarian Neoplasms/epidemiology , Registries , Uterine Cervical Neoplasms/epidemiology , Uterine Neoplasms/epidemiology , Young Adult
4.
Oncogene ; 28(6): 843-53, 2009 Feb 12.
Article in English | MEDLINE | ID: mdl-19079346

ABSTRACT

Increased levels of enhancer of zeste homolog 2 (EZH2), a critical regulator of cellular memory, are associated with negative estrogen receptor (ER) expression and disease progression in breast cancer. High levels of EZH2 signal the presence of metastasis and poor outcome in breast cancer patients. To test the hypothesis that deregulation of EZH2 contributes to ER-negative breast cancer progression, EZH2 expression was inhibited in ER-negative breast cancer cells MDA-MB-231 and CAL51 using a lentivirus system. EZH2 knockdown decreased proliferation and delayed the G(2)/M cell-cycle transition, although not affecting apoptosis. In vivo, EZH2 downregulation significantly decreased breast xenograft growth and improved survival. EZH2 knockdown upregulated BRCA1 protein. Of note, BRCA1 knockdown was sufficient to rescue the effects of EZH2 downregulation on proliferation, G(2)/M arrest, and on the levels of hyperphosphorylated mitotic Cdc25C and Cyclin B1 proteins, crucial for entry into mitosis. Invasive ER-negative breast carcinomas show significant overexpression of EZH2 and downregulation of BRCA1 proteins. Taken together, we show that EZH2 is important in ER-negative breast cancer growth in vivo and in vitro, and that BRCA1 is required for the proliferative effects of EZH2. Blockade of EZH2 may provide a prime target to prevent and/or halt ER-negative breast cancer progression.


Subject(s)
BRCA1 Protein/biosynthesis , Breast Neoplasms/metabolism , DNA-Binding Proteins/biosynthesis , Gene Expression Regulation, Neoplastic , Receptors, Estrogen/metabolism , Transcription Factors/biosynthesis , Animals , Cell Line, Tumor , Cell Proliferation , Disease Progression , Enhancer of Zeste Homolog 2 Protein , Humans , Mammary Neoplasms, Animal/metabolism , Mice , Mice, SCID , Neoplasm Invasiveness , Neoplasm Transplantation , Polycomb Repressive Complex 2
5.
Endocr Relat Cancer ; 11(2): 255-63, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15163301

ABSTRACT

Copper is a tightly regulated trace element. Disruptions of copper homeostasis are rare and they cause serious disorders such as Wilson's disease and Menkes disease. Copper also plays an important role in promoting physiological and malignant angiogenesis. Formation of new blood vessels by a tumor enables tumor growth, invasion and metastasis. The copper chelator tetrathiomolybdate (TM), which quickly and effectively depletes copper stores, is under investigation as an anti-angiogenic agent. Promising results in vitro, in pre-clinical animal models and in an early (phase I) clinical trial have led to ongoing phase II evaluation of TM in patients with advanced cancers.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Chelating Agents/therapeutic use , Copper/deficiency , Molybdenum/therapeutic use , Neoplasms/blood supply , Neovascularization, Pathologic/prevention & control , Animals , Humans , Neoplasms/drug therapy
6.
Soc Sci Med ; 58(7): 1427-42, 2004 Apr.
Article in English | MEDLINE | ID: mdl-14759687

ABSTRACT

With the recent completion of the sequencing of the Human Genome, genetic testing will increasingly become available for a greater number of medical conditions, many of which are those that manifest in adulthood (e.g., various cancers, cardiovascular disease, diabetes) or for which little or no treatments are available (e.g., Alzheimer disease). Genetic services, defined here as those relating to genetic testing and counseling, will be with helping more individuals deal with medical information that affects their health directly, as opposed to affecting primarily the health of their offspring. This paper reviews the existing research in the genetic testing and counseling literature and presents an evaluation framework outlining the intended outcomes of genetic services. The purpose of this framework is to provide an overview of the potential outcomes of these services and highlight constructs for future research in this area. In addition, other issues that will affect the assessment of genetic services are raised, using examples from the existing literature. Ultimately, the goal of this paper is to highlight and suggest directions researchers can take to produce the information needed to guide genetic testing and counseling practice. Moreover, as genetic knowledge is increasingly applied towards the prevention and treatment of various common, chronic disease conditions, genetic information will have implications for providers outside of the traditional medical genetics realm, such as primary care providers and public health practitioners. A better understanding of the outcomes of genetic testing and counseling will provide a basis from which to ensure an appropriate application of genetic information by all those who eventually provide care and "genetic" services.


Subject(s)
Genetic Counseling , Genetic Testing , Decision Making , Genetic Testing/methods , Humans , Informed Consent , Outcome Assessment, Health Care , Physician-Patient Relations , United States
7.
Psychooncology ; 10(5): 349-60, 2001.
Article in English | MEDLINE | ID: mdl-11536413

ABSTRACT

Intrusive thoughts about cancer, often identified as 'cancer-specific worries' or 'cancer-specific distress', have been postulated to be associated with dysfunction in women at increased risk of developing breast or ovarian cancer. The current study discusses the development and validation of a measure designed to assess women's perceptions of the interference such worries create in their daily functioning. Analyses revealed that approximately two-thirds of a high-risk breast cancer clinic sample perceived worries about breast cancer as interfering with their functioning across a variety of life domains. Multiple regression analyses indicated that worry interference scores predicted Profile of Mood States (POMS) Anxiety and Confusion, and Short Form-36 (SF-36) Role-Emotional and Mental Health scores after the effects of other variables such as frequency of worry about breast cancer, and having a family history of cancer had been considered. Women who perceived their worries as interfering with their functioning reported higher levels of anxiety and confusion, and diminished mental health and role functioning. The results add to the expanding area of anxiety/distress in at-risk populations by providing (1) a direct measure of the perceived interference associated with breast cancer-specific thoughts, (2) a validation of the measure via its associations with standard measures of emotional distress and health functioning, and (3) evidence of the measure's incremental predictive value in explaining distress and quality of life, after consideration of background variables, such as having a family history of cancer.


Subject(s)
Attitude to Health , Breast Neoplasms/genetics , Fear , Genetic Predisposition to Disease/psychology , Genetic Testing/psychology , Health Status , Mental Health , Ovarian Neoplasms/genetics , Risk Assessment , Stress, Psychological/etiology , Stress, Psychological/psychology , Surveys and Questionnaires/standards , Women/psychology , Activities of Daily Living , Adult , Factor Analysis, Statistical , Female , Humans , Quality of Life , Regression Analysis , Risk Factors , Role
8.
Laryngoscope ; 111(4 Pt 1): 696-701, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11359142

ABSTRACT

OBJECTIVE: To determine whether tetrathiomolybdate (TM), a powerful chelator of copper, is capable of lowering the body stores of copper and suppressing the growth of head and neck squamous cell carcinoma in an orthotopic murine model. STUDY DESIGN: In vivo, murine model. METHODS: Twelve 8-week-old male C3H/HeJ mice were assigned to either a TM treatment group (n = 7) or a control group (n = 5). Serum samples were obtained from a single mouse in each group to measure the level of ceruloplasmin as a surrogate marker of total body copper on days 0, 4, and 7. Mice in both groups received a floor-of-mouth injection of 1.5 x 105 SCC VII/SF cells. After 7 to 10 days of tumor growth the treatment group received fresh water daily, to which TM was added to achieve an oral intake of 50 mg per mouse. The control group received only fresh drinking water daily. Tumor volume measurements were obtained every other day. Microvessel density counts were assessed in the tumors by Factor VIII analysis. RESULTS: Measurable tumor growth was achieved in 100% of the mice by the tenth day. Total body copper was reduced by 28% from baseline levels in mice in the treatment group. The difference in mean tumor volume in the control group was 4.7 times greater than the TM-treated group at the completion of treatment (3004 mm3 and 633mm3, respectively). This accounted for an overall suppression rate of 79% (P =.008; two-tailed Student t test). In addition, microvessel density was reduced by 50% in the TM-treated group. CONCLUSION: In this initial study, the first of its kind in head and neck squamous cell carcinoma, we have demonstrated the ability of TM to significantly suppress both the growth of squamous cell carcinoma and tumor vascularity in this orthotopic murine model, suggesting its potential for efficacy in the treatment of this disease in humans.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Carcinoma, Squamous Cell/prevention & control , Chelating Agents/therapeutic use , Copper , Head and Neck Neoplasms/prevention & control , Molybdenum/therapeutic use , Animals , Awards and Prizes , Carcinoma, Squamous Cell/blood supply , Ceruloplasmin/analysis , Copper/metabolism , Head and Neck Neoplasms/blood supply , Male , Mice , Mice, Inbred C3H , Neoplasm Transplantation
9.
Mod Pathol ; 14(5): 458-64, 2001 May.
Article in English | MEDLINE | ID: mdl-11353057

ABSTRACT

E-cadherin is a transmembrane glycoprotein that mediates epithelial cell-to-cell adhesion. Because loss of E-cadherin expression results in disruption of cellular clusters, it has been postulated that E-cadherin functions as a tumor suppressor protein. The role of E-cadherin in inflammatory breast cancer (IBC), a distinct and highly aggressive form of breast cancer, is largely unknown. The aim of our study was to elucidate whether E-cadherin expression contributes to the development and progression of the IBC phenotype and to investigate any differences in E-cadherin expression between IBC and stage-matched non-IBC. Forty-two breast cancer cases (20 IBC and 22 non-IBC) were identified. Strict and well-accepted criteria were used for the diagnosis of IBC. Clinical and pathologic features were studied, and formalin-fixed, paraffin-embedded tissue sections were immunostained for E-cadherin, estrogen and progesterone receptors (ER and PR, respectively), and HER2/neu. Statistical analysis was performed using Fisher's exact test. All IBC uniformly expressed E-cadherin, whereas 15 of the 22 (68%) of the non-IBC expressed the protein (P = .006). Intralymphatic tumor emboli in the IBC cases were also all E-cadherin positive. Two IBC tumors demonstrated invasive lobular histology, and both cases were positive for E-cadherin. Of the non-IBC cases, three were invasive lobular carcinomas, and all were positive for E-cadherin. No association was found between E-cadherin expression and ER, PR status, or HER2/neu overexpression. Our study demonstrates that there is a strong association between E-cadherin expression and IBC and suggests that E-cadherin may be involved in the pathogenesis of this form of advanced breast cancer. In our study, we demonstrate that circulating IBC tumor cells strongly express E-cadherin, thereby providing an important exception to the positive association between E-cadherin loss and poor prognosis in breast cancer.


Subject(s)
Breast Neoplasms/metabolism , Cadherins/metabolism , Carcinoma/metabolism , Breast Neoplasms/pathology , Carcinoma/secondary , Female , Humans , Immunohistochemistry , Lymphatic System/pathology , Neoplasm Staging , Neoplastic Cells, Circulating/chemistry , Neoplastic Cells, Circulating/pathology , Receptor, ErbB-2/analysis , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis
10.
Cancer Res ; 60(20): 5832-8, 2000 Oct 15.
Article in English | MEDLINE | ID: mdl-11059780

ABSTRACT

Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer and is phenotypically distinct from other forms of locally advanced breast cancer. In a previous study, we identified specific genetic alterations of IBC that could account for a highly invasive phenotype. RhoC GTPase was overexpressed in 90% of IBC archival tumor samples, but not in stage-matched, non-IBC tumors. To study the role of RhoC GTPase in contributing to an IBC-like phenotype, we generated stable transfectants of human mammary epithelial cells overexpressing the RhoC gene. The HME-RhoC transfectants formed large colonies under anchorage-independent growth conditions, were more motile, and were invasive. In conjunction with an increase in motility, overexpression of RhoC led to an increase in actin stress fiber and focal adhesion contact formation. Furthermore, orthotopic injection into immunocompromised mice led to tumor formation. Taken together, these data indicate that RhoC GTPase is a transforming oncogene in human mammary epithelial cells and can lead to a highly invasive phenotype, akin to that seen in IBC.


Subject(s)
Breast Neoplasms/genetics , Breast/physiology , Cell Transformation, Neoplastic/genetics , GTP Phosphohydrolases/genetics , rho GTP-Binding Proteins/genetics , Animals , Breast/enzymology , Breast Neoplasms/enzymology , Breast Neoplasms/pathology , Cell Adhesion/physiology , Cell Division/physiology , Cell Line, Transformed , Cell Movement/physiology , Cell Transformation, Neoplastic/metabolism , Epithelial Cells/enzymology , Epithelial Cells/physiology , Female , GTP Phosphohydrolases/biosynthesis , Gene Expression , Humans , Mice , Mice, Nude , Neoplasm Invasiveness , Neoplasm Transplantation , Oncogenes , Phenotype , Transfection , ras Proteins , rho GTP-Binding Proteins/biosynthesis , rho GTP-Binding Proteins/metabolism , rhoC GTP-Binding Protein
11.
Clin Cancer Res ; 6(1): 1-10, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10656425

ABSTRACT

Preclinical and in vitro studies have determined that copper is an important cofactor for angiogenesis. Tetrathiomolybdate (TM) was developed as an effective anticopper therapy for the initial treatment of Wilson's disease, an autosomal recessive disorder that leads to abnormal copper accumulation. Given the potency and uniqueness of the anticopper action of TM and its lack of toxicity, we hypothesized that TM would be a suitable agent to achieve and maintain mild copper deficiency to impair neovascularization in metastatic solid tumors. Following preclinical work that showed efficacy for this anticopper approach in mouse tumor models, we carried out a Phase I clinical trial in 18 patients with metastatic cancer who were enrolled at three dose levels of oral TM (90, 105, and 120 mg/day) administered in six divided doses with and in-between meals. Serum ceruloplasmin (Cp) was used as a surrogate marker for total body copper. Because anemia is the first clinical sign of copper deficiency, the goal of the study was to reduce Cp to 20% of baseline value without reducing hematocrit below 80% of baseline. Cp is a reliable and sensitive measure of copper status, and TM was nontoxic when Cp was reduced to 15-20% of baseline. The level III dose of TM (120 mg/ day) was effective in reaching the target Cp without added toxicity. TM-induced mild copper deficiency achieved stable disease in five of six patients who were copper deficient at the target range for at least 90 days.


Subject(s)
Angiogenesis Inhibitors/adverse effects , Molybdenum/adverse effects , Neoplasms/drug therapy , Adult , Angiogenesis Inhibitors/administration & dosage , Animals , Biomarkers/blood , Ceruloplasmin/analysis , Copper/blood , Copper/deficiency , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Male , Mice , Middle Aged , Molybdenum/administration & dosage , Neoplasm Metastasis , Neoplasms/pathology
12.
Neoplasia ; 2(5): 418-25, 2000.
Article in English | MEDLINE | ID: mdl-11191108

ABSTRACT

Inflammatory breast cancer (IBC) is a distinct and aggressive form of locally advanced breast cancer. IBC is highly angiogenic, invasive, and metastatic at its inception. Previously, we identified specific genetic alterations of IBC that contribute to this highly invasive phenotype. RhoC GTPase was overexpressed in 90% of archival IBC tumor samples, but not in stage-matched, non-IBC tumors. To study the role of RhoC GTPase in contributing to an IBC-like phenotype, we generated stable transfectants of human mammary epithelial cells overexpressing the RhoC gene, and studied the effect of RhoC GTPase overexpression on the modulation of angiogenesis in IBC. Levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), interleukin-6 (IL-6), and interleukin-8 (IL-8) were significantly higher in the conditioned media of the HME-RhoC transfectants than in the untransfected HME and HME-beta-galactosidase control media, similar to the SUM149 IBC cell line. Inhibition of RhoC function by introduction of C3 exotransferase decreased production of angiogenic factors by the HME-RhoC transfectants and the SUM149 IBC cell line, but did not affect the control cells. These data support the conclusion that overexpression of RhoC GTPase is specifically and directly implicated in the control of the production of angiogenic factors by IBC cells.


Subject(s)
Adenocarcinoma/pathology , Botulinum Toxins , Breast Neoplasms/pathology , Breast/cytology , Endothelial Growth Factors/biosynthesis , Fibroblast Growth Factor 2/biosynthesis , Gene Expression Regulation, Neoplastic/physiology , Interleukin-6/biosynthesis , Interleukin-8/biosynthesis , Lymphokines/biosynthesis , Neoplasm Proteins/biosynthesis , Neovascularization, Pathologic/enzymology , rho GTP-Binding Proteins/physiology , ADP Ribose Transferases/metabolism , ADP Ribose Transferases/pharmacology , Adenocarcinoma/metabolism , Adenosine Diphosphate Ribose/metabolism , Animals , Aorta/drug effects , Breast/metabolism , Breast Neoplasms/metabolism , Cell Line, Transformed/enzymology , Culture Media, Conditioned/analysis , Culture Media, Conditioned/pharmacology , Endothelial Growth Factors/genetics , Epithelial Cells/metabolism , Female , Fibroblast Growth Factor 2/genetics , Humans , Interleukin-6/genetics , Interleukin-8/genetics , Liposomes , Lymphokines/genetics , Membrane Fusion , Neoplasm Proteins/genetics , Neovascularization, Pathologic/genetics , Protein Processing, Post-Translational , Rats , Rats, Sprague-Dawley , Recombinant Fusion Proteins/physiology , Transfection , Tumor Cells, Cultured/enzymology , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors , rho GTP-Binding Proteins/biosynthesis , rho GTP-Binding Proteins/genetics , rhoC GTP-Binding Protein
13.
Breast Cancer Res ; 2(6): 423-9, 2000.
Article in English | MEDLINE | ID: mdl-11250736

ABSTRACT

Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer (LABC) that effects approximately 5% of women with breast cancer annually in the USA. It is a clinically and pathologically distinct form of LABC that is particularly fast growing, invasive, and angiogenic. Nearly all women have lymph node involvement at the time of diagnosis, and approximately 36% have gross distant metastases. Despite recent advances in multimodality treatments, the prognosis of patients with IBC is poor, with a median disease-free survival of less than 2.5 years. Recent work on the genetic determinants that underlie the IBC phenotype has led to the identification of genes that are involved in the development and progression of this disease. This work has been aided by the establishment of primary human cell lines and animal models. These advances suggest novel targets for future interventions in the diagnosis and treatment of IBC.


Subject(s)
Breast Neoplasms/pathology , Carcinoma/pathology , Animals , Breast Neoplasms/genetics , Breast Neoplasms/mortality , Breast Neoplasms/therapy , Carcinoma/genetics , Carcinoma/mortality , Carcinoma/therapy , Chemotherapy, Adjuvant , Clinical Trials as Topic , Combined Modality Therapy , Cytokines/physiology , Disease-Free Survival , Endothelial Growth Factors/physiology , Estrogens , Female , Genes, p53 , Humans , Inflammation , Lymphatic Metastasis , Lymphokines/physiology , Mice , Neoplasm Invasiveness/genetics , Neoplasm Metastasis , Neoplasm Proteins/analysis , Neoplasms, Hormone-Dependent/genetics , Neoplasms, Hormone-Dependent/mortality , Neoplasms, Hormone-Dependent/pathology , Neoplasms, Hormone-Dependent/therapy , Neovascularization, Pathologic/genetics , Oncogenes , Progesterone , Prognosis , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Survival Analysis , Transplantation, Heterologous , Tumor Cells, Cultured , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
14.
Clin Cancer Res ; 5(9): 2511-9, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10499627

ABSTRACT

Inflammatory breast cancer is a rapidly growing, distinct form of locally advanced breast cancer that carries a guarded prognosis. To identify the genes that contribute to this aggressive phenotype, we compared under- and overexpressed sequences in an inflammatory breast tumor cell line with those of actively replicating normal human mammary epithelial cell lines using differential display. Of the 17 transcripts isolated and characterized from these experiments, overexpression of RhoC GTPase and loss of expression of a novel gene on 6q22, LIBC (lost in inflammatory breast cancer), were highly correlated (P<0.0095 and P<0.0013, respectively) with the inflammatory phenotype when a panel of archival inflammatory breast cancers was compared with noninflammatory stage III breast cancers by in situ hybridization. This study suggests two new molecular markers specific for inflammatory breast cancer.


Subject(s)
Biomarkers, Tumor/genetics , Breast Neoplasms/genetics , Breast Neoplasms/pathology , GTP Phosphohydrolases/genetics , Immediate-Early Proteins , Insulin-Like Growth Factor Binding Proteins/genetics , Insulin-Like Growth Factor Binding Proteins/metabolism , Intercellular Signaling Peptides and Proteins , Neoplasm Proteins/genetics , rho GTP-Binding Proteins/genetics , Amino Acid Sequence , Animals , Biomarkers, Tumor/isolation & purification , Breast/cytology , Breast Neoplasms/enzymology , Breast Neoplasms/metabolism , CCN Intercellular Signaling Proteins , Cattle , Connective Tissue Growth Factor , Epithelial Cells/metabolism , GTP Phosphohydrolases/biosynthesis , Genes, Tumor Suppressor , Growth Substances/chemistry , Humans , Insulin-Like Growth Factor Binding Proteins/isolation & purification , Mice , Molecular Sequence Data , Neoplasm Proteins/isolation & purification , Neoplasm Proteins/metabolism , Phenotype , RNA, Messenger/isolation & purification , RNA, Messenger/metabolism , Reproducibility of Results , Swine , Transcription, Genetic , Tumor Cells, Cultured , ras Proteins , rho GTP-Binding Proteins/biosynthesis , rhoC GTP-Binding Protein
16.
J Clin Oncol ; 15(8): 2873-81, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9256131

ABSTRACT

PURPOSE: To determine whether breast conservation and prolonged neoadjuvant chemotherapy have efficacy in locally advanced breast cancer (LABC), as measured by survival and rate of breast conservation. MATERIALS AND METHODS: Eighty-nine patients with stage III disease were enrolled at the University of Michigan (UM) onto a prospective nonrandomized trial. Patients received nine 21-day cycles of neoadjuvant chemohormonal therapy that consisted of doxorubicin 30 mg/m2 and cyclophosphamide 750 mg/m2 intravenously on day 1, conjugated estrogens 0.625 mg orally twice daily on days 6 to 8, methotrexate 40 mg/m2 and fluorouracil 500 mg/m2 intravenously on day 8, and tamoxifen 10 mg orally twice daily on days 9 to 14. Patients with a negative biopsy received radiation only, while those with residual disease underwent mastectomy and postoperative radiotherapy. Eight more cycles of chemohormonal therapy were administered after local-regional therapy. RESULTS: The clinical response rate to neoadjuvant therapy was 97%, 28% of patients had a complete pathologic response evaluated at biopsy. Five-year overall and disease-free survival probabilities were 54% and 44%, respectively. The median disease-free survival time was 2.4 years. The 5-year actuarial rates of local-regional control with local failure as only first failure were 82% and 78% following radiotherapy, and mastectomy and radiotherapy, respectively (P = .99). CONCLUSION: Prolonged neoadjuvant chemohormonal therapy and biopsy-driven local therapy have efficacy in LABC, with 28% of patients being candidates for breast conservation and a 5-year overall survival rate of 54%.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/therapy , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Breast Neoplasms/radiotherapy , Combined Modality Therapy , Female , Humans , Mastectomy , Middle Aged , Neoplasm Recurrence, Local , Prognosis , Prospective Studies , Survival Rate
17.
AJR Am J Roentgenol ; 168(6): 1599-602, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9168735

ABSTRACT

OBJECTIVE: We describe for the first time (to our knowledge) the mammographic appearance of breast cancer and breast density in carriers of the breast cancer gene BRCA1. CONCLUSION: The mammographic appearance of breast cancer in BRCA1 carriers was similar to that in the general population. All mammographic densities were observed. Appropriate mammographic management of these extremely high-risk patients is yet to be determined.


Subject(s)
Breast Neoplasms/diagnostic imaging , Breast Neoplasms/genetics , Carcinoma in Situ/diagnostic imaging , Carcinoma in Situ/genetics , Carcinoma, Ductal, Breast/diagnostic imaging , Carcinoma, Ductal, Breast/genetics , Genes, BRCA1/genetics , Adult , Female , Humans , Mammography , Middle Aged , Mutation , Risk Factors
18.
Genomics ; 37(2): 161-71, 1996 Oct 15.
Article in English | MEDLINE | ID: mdl-8921387

ABSTRACT

Recent transcription mapping efforts within chromosome 17q21 have led to the identification of a human homolog of the Drosophila gene Enhancer of zeste, E(z). A member of the Polycomb group (Pc-G) of proteins, Drosophila E(z) acts as a negative regulator of the segment identity genes of the Antennapedia and Bithorax complexes. Here we report the full-length protein coding sequence of human EZH1 (Enhancer of zeste homolog 1) and compare the respective protein sequences in both species. EZH1 encodes a protein of 747 amino acids that displays 55% amino acid identity overall (70% similarity) with Drosophila E(z). The strongest homology was noted (79% identity, 89% similarity) within the carboxy-terminal 245 amino acids, including the SET domain, a region of E(z) also conserved in other Drosophila proteins with roles in development and/or chromatin structure. A large Cysrich region with a novel spatial pattern of cysteine residues was also conserved in both EZH1 and E(z). The strong sequence conservation suggest potential roles for EZH1 in human development as a transcriptional regulator and as a component of protein complexes that stably maintain heterochromatin. EZH1 is expressed as two major transcripts in all adult and fetal human tissues surveyed; comparison of cloned cDNAs suggests that alternative splicing may account for at least part of the transcript size difference. Analysis of one cDNA revealed an unusual splicing event involving EZH1 and a tandemly linked gene GPR2 and suggests a potential mechanism for modifying the EZH1 protein in the conserved C-terminal domain. The sequence and isolated cDNAs will provide useful reagents for determining the function of EZH1 and the importance of the evolutionarily conserved domains.


Subject(s)
BRCA1 Protein/genetics , Drosophila Proteins , Insect Proteins/genetics , Nuclear Proteins , Proteins/genetics , Repressor Proteins , Adult , Animals , Chromosome Mapping , Chromosomes, Human, Pair 17 , Cloning, Molecular , DNA, Complementary , DNA-Binding Proteins , Drosophila , Gene Expression , Humans , Mice , Molecular Sequence Data , Polycomb Repressive Complex 2 , Polymorphism, Genetic , Sequence Homology, Amino Acid , Transcription Factors
19.
Am J Pathol ; 148(5): 1671-8, 1996 May.
Article in English | MEDLINE | ID: mdl-8623934

ABSTRACT

Defective DNA mismatch repair in neoplasia is manifested by extra, aberrant bands within multiple microsatellite markers. The replication error (RER) phenotype is present in most colorectal and endometrial carcinomas in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. In addition, a minority of sporadic colorectal and endometrial carcinomas are RER positive. RER in sporadic colorectal carcinomas has been associated with improved prognosis, but its clinical significance in sporadic endometrial cancer has not been characterized. We analyzed DNA extracted from 109 formalin-fixed sporadic endometrial carcinomas for microsatellite instability. The RER-positive phenotype was demonstrated by microsatellite instability in more than one of the eight dinucleotide markers tested. RER was correlated with pathological and clinical parameters as well as with immunohistochemical staining for the p53 gene product and alterations in codon 12 of Ki-ras. Nine percent of the endometrial carcinomas were RER positive, and RER was significantly associated with high grade and adverse outcome. We found no significant correlation of RER with histological subtype, stage, depth of invasion, mutations in the 12th codon of Ki-ras, or p53 immunoreactivity. We conclude that the RER phenotype is present in a minority of sporadic endometrial carcinomas and is associated with high grade and poor prognosis.


Subject(s)
DNA, Neoplasm/genetics , Endometrial Neoplasms/genetics , Microsatellite Repeats/genetics , Adult , Aged , Aged, 80 and over , Base Sequence , DNA Primers/chemistry , Endometrial Neoplasms/chemistry , Endometrial Neoplasms/pathology , Female , Gene Expression Regulation, Neoplastic , Genes, p53/genetics , Genes, ras/genetics , Genotype , Humans , Immunohistochemistry , Middle Aged , Molecular Sequence Data , Mutation , Phenotype , Polymerase Chain Reaction , Prognosis , Tumor Suppressor Protein p53/analysis , Tumor Suppressor Protein p53/genetics , ras Proteins/analysis , ras Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...